A database of FDA approved therapeutic peptides and proteins
ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1098 | Th1014 | Salmon Calcitonin | CSNLSTCVLGKLSQELHKLQ Full view | 32 | Ib | Osteological | Calcimar | N.A. | Solution | Subcutaneous or Intramuscular Injection | Bone Density Conservation Agents, Antihypercalcemic agents, Anti-osteoporotic agents | Calcitonin receptor |
1099 | Th1014 | Salmon Calcitonin | CSNLSTCVLGKLSQELHKLQ Full view | 32 | Ib | Osteological | Fortical | N.A. | Nasal spray | Intranasal use | Bone Density Conservation Agents, Antihypercalcemic agents, Anti-osteoporotic agents | Calcitonin receptor |
1100 | Th1014 | Salmon Calcitonin | CSNLSTCVLGKLSQELHKLQ Full view | 32 | Ib | Osteological | Miacalcin | Novartis | Solution | Subcutaneous or Intramuscular Injection | Bone Density Conservation Agents, Antihypercalcemic agents, Anti-osteoporotic agents | Calcitonin receptor |
1205 | Th1027 | Insulin Regular | A-chain:GIVEQCCTSIC< Full view | 51 | Ia | Genetic/Hormonal | Humulin R | Eli Lilly and Company | Sterile, clear, aqueous, and colorless solution | Subcutaneous injection in the abdominal wall, the thigh, the gluteal region or in the upper arm and Intravenousadministration of Humulin R (insulin (human recombinant)) U-100 is possible under medical supervision. | Antidiabetic Agents | Insulin receptor,Insulin-like growth factor 1 receptor,Retinoblastoma-associated protein,Cathepsin D,Insulin-degrading enzyme,Neuroendocrine convertase 2,Carboxypeptidase E,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-r |
1206 | Th1027 | Insulin Regular | A-chain:GIVEQCCTSIC< Full view | 51 | Ia | Genetic/Hormonal | Novolin R | Novo Nordisk | Sterile, clear, aqueous, and colorless solution | Subcutaneous and Intravenous infusion | Antidiabetic Agents | Insulin receptor,Insulin-like growth factor 1 receptor,Retinoblastoma-associated protein,Cathepsin D,Insulin-degrading enzyme,Neuroendocrine convertase 2,Carboxypeptidase E,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-r |
1275 | Th1040 | Insulin Lispro | A chain:GIVEQCCTSICS Full view | 51 | Ia | Hormonal/Metabolic/genetic | Humalog | Eli Lilly | Sterile, aqueous, clear, and colorless solution | Subcutaneous and Intravenous infusion | Hypoglycemic Agents, Antidiabetic agents | Insulin receptor,Insulin-like growth factor 1 receptor |
1276 | Th1040 | Insulin Lispro | A chain:GIVEQCCTSICS Full view | 51 | Ia | Hormonal/Metabolic/genetic | Humalog KwikPen | Eli Lilly | Solution | Subcutaneous injection | Hypoglycemic Agents, Antidiabetic agents | Insulin receptor,Insulin-like growth factor 1 receptor |
1277 | Th1040 | Insulin Lispro | A chain:GIVEQCCTSICS Full view | 51 | Ia | Hormonal/Metabolic/genetic | Humalog Pen | Eli Lilly | N.A. | N.A. | Hypoglycemic Agents, Antidiabetic agents | Insulin receptor,Insulin-like growth factor 1 receptor |
1283 | Th1041 | Insulin Glargine | A-chain:GIVEQCCTSICS Full view | 53 | Ia | Hormonal/Metabolic/genetic | Lantus | Sanofi-Aventis | Solution | Subcutaneous injection | Hypoglycemic Agents, Antidiabetic agents | Insulin receptor,Insulin-like growth factor 1 receptor |
1284 | Th1041 | Insulin Glargine | A-chain:GIVEQCCTSICS Full view | 53 | Ia | Hormonal/Metabolic/genetic | Lantus OptiSet | N.A. | Solution | Subcutaneous injection | Hypoglycemic Agents, Antidiabetic agents | Insulin receptor,Insulin-like growth factor 1 receptor |
1285 | Th1041 | Insulin Glargine | A-chain:GIVEQCCTSICS Full view | 53 | Ia | Hormonal/Metabolic/genetic | Lantus SoloStar | N.A. | Solution | Subcutaneous injection | Hypoglycemic Agents, Antidiabetic agents | Insulin receptor,Insulin-like growth factor 1 receptor |
1382 | Th1060 | Insulin, porcine | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | vetsulin | Intervet Inc (Merck Animal Health) | Sterile injectable suspension in multidose vials containing 10 mL of 40 IU/mL porcine insulin zinc suspension | Subcutaneous Injection | Hypoglycemic Agents | Interferon alpha/beta receptor 2,Interferon alpha/beta receptor 1, Hyaluronan, Transforming growth factor beta-1 |
1462 | Th1088 | Enfuvirtide | YTSLIHSLIEESQNQQEKNE Full view | 36 | IIa | Infectious | `FUZEON | Trimeris, Roche | White to off-white, sterile, lyophilized powder. | Subcutaneous injection | HIV Fusion Inhibitors | Oxytocin receptor,Oxytocin-neurophysin 1, Envelope glycoprotein |
1478 | Th1098 | Exenatide | HGEGTFTSDLSKQMEEEAVR Full view | 39 | Ib | Hormonal/Metabolic | BYETTA | N.A. | N.A. | N.A. | Hypoglycemic Agents | Glucagon-like peptide 1 receptor |
1479 | Th1098 | Exenatide | HGEGTFTSDLSKQMEEEAVR Full view | 39 | Ib | Hormonal/Metabolic | BYDUREON | Amylin Pharmaceuticals | White to off-white powder that is available in a dosage strength of 2 mg exenatide per vial or per pen | N.A. | Hypoglycemic Agents | Glucagon-like peptide 1 receptor |
1482 | Th1100 | Pramlintide | KCNTATCATQRLANFLVHSS Full view | 37 | Ia | Hormonal/Metabolic | Symlin | Amylin Pharmaceuticals (now a wholly owned subsidiary of AstraZeneca) | Clear, isotonic, sterile solution | Subcutaneous injection | N.A. | Calcitonin receptor,Receptor activity-modifying protein 1,Receptor activity-modifying protein 2,Receptor activity-modifying protein 3 |
1501 | Th1104 | Corticotropin | SYSMEHFRWGKPVGKKRRPV Full view | 39 | IV | Hormonal | H.P. Acthar | Questcor Pharmaceuticals, Inc. | N.A. | N.A. | N.A. | N.A. |
1502 | Th1105 | Insulin Aspart | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | NovoLog | Novo Nordisk | Sterile, aqueous, clear, and colorless solution | Subcutaneous injection, Intravenous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
1503 | Th1105 | Insulin Aspart | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | NovoLog Mix 50/50 | Novo Nordisk | Uniform, white, sterile suspension that contains insulin aspart | Subcutaneous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
1504 | Th1105 | Insulin Aspart | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | NovoLog Mix 70/30 | Novo Nordisk | Uniform, white, sterile suspension that contains insulin aspart 100 Units/mL. | Subcutaneous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
1511 | Th1106 | Insulin Detemir | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | LEVEMIR | Novo Nordisk | Clear, colorless, aqueous, neutral sterile solution | Subcutaneous injection | Antidiabetic Agents | Insulin receptor |
1520 | Th1107 | Insulin Glulisine | A chain: GIVEQCCTSIC Full view | 51 | Ib | Hormonal/Metabolic | APIDRA | sanofi-aventis | Sterile, aqueous, clear, and colorless solution | N.A. | Antidiabetic Agents | Insulin receptor |
1530 | Th1109 | Nesiritide | SPKMVQGSGCFGRKMDRISS Full view | 32 | Ib | Cardiac | NATRECOR | Scios unit of Johnson & Johnson, | White- to off-white lyophilized powder | Intravenous injection | N.A. | N.A. |
1534 | Th1113 | Glatiramer Acetate | EAYKAAEKAYAAKEAAKEAA Full view | 52 | IIa | Neurological Disorder | Copaxone | Teva Pharmaceutical Industries | Clear, colorless to slightly yellow, sterile, nonpyrogenic solution | Subcutaneous injection | N.A. | N.A. |
1556 | Th1120 | Teriparatide | Parathyroid hormone Full view | 34 | Ib | Osteological | Forteo | Eli Lilly and Company | Sterile, colorless, clear, isotonic solution | Subcutaneous injection | Bone Density Conservation Agents | Parathyroid hormone/parathyroid hormone-related peptide receptor |
1576 | Th1124 | Liraglutide | HAEGTFTSDVSSYLEGQAAK Full view | 33 | Ib | Hormonal | Saxenda | Novo Nordisk | Clear, colorless solution | Subcutaneous injection | N.A. | Glucagon-like peptide 1 receptor |
1577 | Th1124 | Liraglutide | HAEGTFTSDVSSYLEGQAAK Full view | 33 | Ib | Hormonal | Victoza | Novo Nordisk | Clear, colorless solution. | Subcutaneous injection | N.A. | Glucagon-like peptide 1 receptor |
1603 | Th1129 | Tesamorelin | YADAIFTNSYRKVLGQLSAR Full view | 44 | Ib | Hormonal | Egrifta | Theratechnologies | Sterile, white to off-white, preservative-free lyophilized powder | Subcutaneous injection | N.A. | Growth hormone-releasing hormone receptor |
1624 | Th1137 | Teduglutide | HGDGSFSDEMNTILDNLAAR Full view | 33 | Ia | Malabsorption disorder | Gattex | NPS Pharmaceuticals, Inc | Clear, colorless to light-straw–colored liquid. | Subcutaneous injection | N.A. | Glucagon-like peptide 2 receptor |
1634 | Th1140 | Insulin, Isophane Or Nph Insulin (Neutral Protamine Hagedorn) | A chain: GIVEQCCTSIC Full view | 51 | Ia | Hormonal/Metabolic | Novolin N | Novo Nordisk | Novolin N InnoLet (nph, human insulin isophane suspension 3 ml disposable prefilled syringe) | Subcutaneous injection | Hypoglycemic Agents and Antidiabetic Agents | Insulin receptor |
1667 | Th1158 | Aprotinin | RPDFCLEPPYTGPCKARIIR Full view | 58 | IIa | Immunological | Trasylol | Bayer Pharmaceuticals | Clear, colorless, sterile isotonic solution | Intravenous administration | N.A. | Trypsin-1, Chymotrypsinogen B, Plasminogen, Kallikrein-! |